If you have tried CBD oil for chronic pain and wondered why it did not help as much as you hoped, you are not alone. But the question worth asking is not whether cannabinoids work. It is whether what you bought is actually what you needed.
CBD vs medical cannabis in the UK is not a comparison between two versions of the same thing. They are legally, clinically, and practically different products, and for pain patients that distinction matters a great deal.
Checking your eligibility for medical cannabis takes only a few minutes, completing which will put you on a pathway to legalised medical cannabis in the UK.
Key Takeaways
- High-street CBD is a food supplement. A CBPM is a prescription medicine. They are not the same thing.
- Over 60% of UK CBD products are inaccurately labelled. Nearly half contain traces of controlled substances.
- Prescribed CBPMs are pharmaceutical-grade, independently tested, and clinically dosed by a specialist.
- The evidence for CBPMs in chronic pain is substantially stronger than for over-the-counter CBD.
- Medical cannabis has been prescribed five times on the NHS since it became legal in 2018.
What Is CBD and What Is It Not?
CBD is one of over 100 compounds found in the cannabis plant. It is non-psychoactive, meaning it does not produce intoxication. In the UK, hemp-derived CBD products with a THC content below the legal threshold can be sold as food supplements or cosmetics, regulated by the Food Standards Agency (FSA) under novel food legislation. They are not medicines.
Because CBD retailers cannot legally make medical claims, these products are marketed in wellness language rather than clinical terms. That matters for pain patients. A product that cannot legally claim to treat your condition has not been required to prove that it does. The FSA’s novel food authorisation process for CBD supplements is ongoing, and no authorisations have been granted as of July 2026.⁵
This does not mean CBD is useless. It occupies a legitimate space. The problem for pain patients is the gap between what the label says and what the product contains.
The Quality Problem With Over-the-Counter CBD
Over-the-counter CBD products in the UK are food supplements, not regulated medicines. Independent studies have found that more than 60% of UK CBD products contain less CBD than stated on the label, and nearly half contain traces of THC or other controlled substances. There is no legal requirement for CBD manufacturers to meet pharmaceutical quality standards.
A 2019 independent analysis by the Centre for Medicinal Cannabis tested 30 commercially available UK CBD products.
- Over 60% inaccurately labelled their CBD content. ³
- Eleven contained less than half the stated CBD. ³
- One contained no CBD at all. ³
- Nearly half contained measurable THC. ³
A 2022 peer-reviewed study found that 55% of UK over-the-counter CBD products tested contained controlled substances including THC and CBN above the legal limit.⁴
For a pain patient relying on a specific dose for symptom management, this inconsistency is a serious practical problem. You may not know whether a product worked, failed, or was never what it claimed to be.
What Is a CBPM and How Is It Different?
A cannabis-based product for medicinal use (CBPM) is a prescription medicine, rescheduled from Schedule 1 to Schedule 2 in November 2018 and legally prescribable only by GMC-registered specialist doctors.¹
CBPMs are manufactured to Good Manufacturing Practice (GMP) pharmaceutical standards, independently tested for potency and purity, and dispensed by licensed pharmacies. The dose, formulation, and product are determined by a specialist clinician based on the patient’s condition, medical history, and treatment background.
The difference between CBD and CBPM is not primarily one of strength. It is one of regulatory category, manufacturing standard, clinical oversight, and formulation. Many CBPMs contain both CBD and THC in ratios the prescribing specialist considers appropriate for the individual.
THC plays a direct role in pain modulation by binding to cannabinoid receptors in the central nervous system. Most over-the-counter CBD products contain little or no THC at meaningful levels, which is part of why prescription cannabis vs CBD oil produces meaningfully different outcomes for many pain patients.
What Does the Evidence Actually Show?
Let’s understand what evidence actually shows:
Evidence for Over-the-Counter CBD in Chronic Pain
The CBD oil for chronic pain evidence picture is limited. Most clinical trials have used pharmaceutical-grade cannabidiol at precisely controlled doses, not the high-street CBD supplements patients actually buy. The evidence from those trials cannot be reliably applied to products with inconsistent labelling and variable potency. The National Institute for Health and Care Excellence (NICE) has not approved CBD supplements for any pain indication.
Evidence for Prescribed CBPMs in Chronic Pain
The evidence base for CBPMs is substantially larger and more clinically rigorous. The UK Medical Cannabis Registry (UKMCR) found statistically significant improvements in Brief Pain Inventory (BPI) scores in chronic pain patients at one, three, and six months following CBPM treatment.⁶ Project Twenty21 (T21), the UK’s largest observational medicinal cannabis registry, enrolled over 4,000 patients.
At three months, chronic pain patients showed significant improvements in pain intensity, pain interference, quality of life, mood, and sleep.⁷
Among opioid-using patients, average daily opioid dose fell from 45mg to 19mg morphine milligram equivalent (MME), an observational finding consistent with an opioid-sparing effect.
A 2025 Phase 3 randomised controlled trial published in Nature Medicine found that a full-spectrum cannabis extract, which includes both THC and CBD, reduced chronic lower back pain significantly more than placebo over 12 weeks.⁸
The evidence for prescribed CBPMs in chronic pain is not definitive, but the body of real-world evidence from UK patient registries is substantially larger, more consistent, and more clinically rigorous than the evidence available for over-the-counter CBD.
For patients exploring this further, explore our chronic pain conditions, covering the specific conditions assessed at LeafEase.
So, Which Is Right for You?
Consider someone who has been managing fibromyalgia for two years and spending around £60 per month on high-street CBD oil. They noticed some improvement initially, but effects have plateaued and their sleep and pain remain significantly disrupted. They have also tried two prescribed medications that either did not help enough or caused side effects they could not tolerate. That history, combined with the documented limitations of OTC CBD quality, is exactly the kind of situation a specialist reviews when assessing whether a CBPM prescription is appropriate.
Your Next Step with LeafEase
At LeafEase, consultations take place by video with a GMC-registered specialist clinician. No GP referral is needed. Medication starts from approximately £50 per month at the lower end, and the LeafEase Advantage subscription is at approximately £31.99 per month (check pricing for further breakdown and discounts) which includes follow-up consultations with the same clinician, formulation reviews built around your daily routine, and free home delivery.
Medication is dispensed by a licensed UK pharmacy partner and arrives in plain, discreet packaging with no indication of the contents on the outside. For a full overview of the process, see how the consultation and prescription process works at LeafEase.
If CBD has not given you the pain relief you needed, the issue may be the product rather than the cannabinoid. Checking your eligibility takes a few minutes and costs nothing.
Frequently Asked Questions
What is the legal difference between CBD oil and a CBPM in the UK?
CBD oil is a food supplement regulated by the FSA. A CBPM is a Schedule 2 prescription medicine regulated by the MHRA. CBD retailers cannot legally make medical claims. CBPMs can only be prescribed by a GMC-registered specialist and dispensed by a licensed pharmacy.
Why does a CBPM contain THC when CBD oil does not?
THC binds directly to cannabinoid receptors involved in pain modulation in a way that CBD alone does not. Most CBPMs prescribed for chronic pain contain both THC and CBD in clinically determined ratios. The specialist selects the formulation based on your condition and history, not a fixed rule.
Can I take CBD supplements alongside a CBPM prescription?
Tell your prescribing clinician about any CBD supplements you are using before starting a CBPM prescription. While CBD supplements are generally low-risk, the clinician needs a complete picture of everything you are taking to assess interactions and determine the right formulation and dose.
Does the FSA regulate CBD products for safety?
The FSA oversees CBD as a novel food, which means manufacturers must submit applications for authorisation. As of July 2026, no CBD food supplements have received full authorisation for medicinal use. Products can be sold pending the outcome, but there is no requirement to prove efficacy or meet pharmaceutical manufacturing standards.
Will switching from CBD to a CBPM mean I feel intoxicated?
Not necessarily. CBPMs are formulated to manage symptoms at clinically appropriate doses, not to produce intoxication. Many patients, particularly those starting on lower-THC or CBD-dominant formulations, report no significant psychoactive effect. Your specialist will discuss what to expect based on the specific product and dose prescribed.
How do I know if a CBPM would work better for me than CBD oil?
If you have a confirmed diagnosis, have tried at least two treatments without adequate relief, and are still experiencing significant symptoms, a specialist consultation is the only way to get a properly assessed answer. An eligibility check at leafease is the first step.
References
[1] NHS England (2023) Cannabis-based products for medicinal use (CBPMs). Available at: https://www.england.nhs.uk/long-read/cannabis-based-products-for-medicinal-use-cbpms/ [Accessed: July 2026].
[2] Medicines and Healthcare products Regulatory Agency (MHRA) (2024) Drug licensing factsheet: cannabis, CBD and other cannabinoids. Available at: https://www.gov.uk/government/publications/cannabis-cbd-and-other-cannabinoids-drug-licensing-factsheet/drug-licensing-factsheet-cannabis-cbd-and-other-cannabinoids [Accessed: July 2026].
[3] Centre for Medicinal Cannabis / NORML (2019) CBD in the UK: independent testing report. Available at: https://norml.org/news/2019/08/15/report-cbd-products-available-in-the-uk-often-mislabeled-possess-variable-quality/ [Accessed: July 2026].
[4] Liebling, J.P., Clarkson, N.J., Gibbs, B.W., Yates, A.S. & O’Sullivan, S.E. (2021) An Analysis of Over-the-Counter Cannabidiol Products in the United Kingdom. PubMed Central, PMC9070743. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC9070743/ [Accessed: July 2026].
[5] Food Standards Agency (2025) CBD Novel Food Applications: consultation August 2025. Available at: https://www.food.gov.uk/our-work/consultation-pack-on-applications-for-authorisation-of-3-cbd-food-products-as-novel-foods [Accessed: July 2026].
[6] Lintzeris, N. et al. (2021) Clinical outcome data of first cohort of chronic pain patients treated with cannabis-based sublingual oils in the United Kingdom: analysis from the UK Medical Cannabis Registry. PubMed Central. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC9292210/ [Accessed: July 2026].
[7] Lynskey, M.T., Schlag, A.K., Athanasiou-Fragkouli, A., Badcock, D. & Nutt, D.J. (2023) Characteristics of and 3-month health outcomes for people seeking treatment with prescribed cannabis: Real-world evidence from Project Twenty21. Drug Science, Policy and Law, 9, 20503245231167373. Available at: https://journals.sagepub.com/doi/full/10.1177/20503245231167373 [Accessed: July 2026].
[8] Karst, M., Meissner, W., Sator, S., Keßler, J., Schoder, V. & Häuser, W. (2025) Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial. Nature Medicine, 31, pp.4189-4196. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC12705446/ [Accessed: July 2026].
